VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 333 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2016. The put-call ratio across all filers is 1.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $39,000 | -15.2% | 2,258 | -45.7% | 0.04% | -2.6% |
| Q1 2017 | $46,000 | -72.8% | 4,158 | -64.3% | 0.04% | -45.7% |
| Q4 2016 | $169,000 | -47.8% | 11,658 | -11.7% | 0.07% | -67.4% |
| Q3 2016 | $324,000 | +390.9% | 13,200 | +300.0% | 0.22% | +338.8% |
| Q2 2016 | $66,000 | -38.9% | 3,300 | -19.5% | 0.05% | -34.7% |
| Q1 2016 | $108,000 | – | 4,100 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,577,892 | $994,984,000 | 31.62% |
| Ruane, Cunniff & Goldfarb | 33,922,192 | $6,051,041,000 | 31.06% |
| LeVasseur Capital Partners LLC | 162,394 | $28,968,000 | 29.76% |
| FARLEY CAPITAL L.P. | 192,130 | $34,272,000 | 27.18% |
| Pershing Square Capital Management | 19,473,933 | $3,473,760,000 | 24.90% |
| Arrow Capital Management, LLC | 109,461 | $19,525,000 | 16.53% |
| Marble Arch Investments | 1,196,900 | $213,503,000 | 16.43% |
| Tesuji Partners | 1,368,040 | $244,414,000 | 15.82% |
| ValueAct Holdings | 14,994,261 | $2,674,676,000 | 15.55% |
| Hound Partners | 3,898,648 | $695,441,000 | 15.04% |